{
    "title": "112_hr5853",
    "content": "The \"Gray Market Drug Reform and Transparency Act of 2012\" prohibits wholesale distributors from purchasing prescription drugs from pharmacies. The \"Gray Market Drug Reform and Transparency Act of 2012\" prohibits wholesale distributors from purchasing prescription drugs from pharmacies, with penalties for violations including misbranding. Additionally, wholesale distributors are required to report on their purchases of prescription drugs. The \"Gray Market Drug Reform and Transparency Act of 2012\" mandates that wholesale distributors report their information to the Secretary annually, including contact details, licensing information, and other relevant data. The \"Gray Market Drug Reform and Transparency Act of 2012\" requires wholesale distributors to report information to the Secretary, including details about additional establishments where drugs are distributed interstate. Reporting requirements are outlined in subsections of the Federal Food, Drug, and Cosmetic Act. The Federal Food, Drug, and Cosmetic Act is amended to include a reporting number and expand public availability of information through a database maintained by the Secretary. The Federal Food, Drug, and Cosmetic Act is amended to include a reporting number and expand public availability of information through a database maintained by the Secretary, including restrictions on disclosure related to storage facility security. Conforming amendments are made to ensure reporting compliance. The Federal Food, Drug, and Cosmetic Act is amended to include reporting requirements for interstate commerce distribution violations and updates to section 510. The Federal Food, Drug, and Cosmetic Act is amended to include reporting requirements for interstate commerce distribution violations and updates to section 510. Paragraph (5) is redesignated as paragraph (4), with an insertion for reporting. Every establishment used for wholesale distribution of drugs subject to section 503(b)(1) must be inspected. The Federal Food, Drug, and Cosmetic Act is amended to include reporting requirements for interstate commerce distribution violations. The provisions of this subsection apply to persons required to report for wholesale distribution of drugs subject to section 503(b)(1) in the same manner as registration requirements, with references to manufacturing and drugs adjusted accordingly. Reports under subsection (b)(3), (c), and (d) are also required. The Federal Food, Drug, and Cosmetic Act is amended to include reporting requirements for interstate commerce distribution violations, with a focus on actions taken by States against wholesale distributors of prescription drugs. The Secretary is tasked with encouraging States to report relevant information to the FDA. The Federal Food, Drug, and Cosmetic Act is amended to include reporting requirements for interstate commerce distribution violations. This includes actions taken by States against wholesale distributors of prescription drugs. The Secretary is responsible for encouraging States to report relevant information to the FDA. Fees for reporting are addressed in Subchapter C of chapter VII. \"Authority to assess and collect fees for wholesale distributors of prescription drugs.\" The Secretary will assess and collect fees from wholesale distributors of drugs in interstate commerce to cover costs for fiscal years 2013 onwards. The amount of fees will be determined by regulations to generate revenue not exceeding 100 percent of the costs incurred. The Secretary will assess fees based on annual revenues, with fees collected to cover FDA costs for reporting requirements and database maintenance. Fees collected are subject to appropriation Acts and remain available until expended. For fiscal years 2013 through 2017, fees collected under this section are authorized to be appropriated to cover FDA costs. Any excess fees collected will be offset against the cumulative amount appropriated. In fiscal year 2016, any excess fees collected under this section will be credited to the FDA's appropriation account and subtracted from the fees authorized for collection in fiscal year 2017. SEC. 4. IDENTIFICATION OF SALES PRICE FOR DRUGS IN SHORTAGE. SEC. 4 amends section 503(e) of the Federal Food, Drug, and Cosmetic Act to identify sales prices for drugs in shortage. It defines \"in shortage\" as listed on the FDA's public website at the time of sale. The amendment applies to drug sales occurring on or after a specified date. Sales of a drug must occur 1 year after the enactment of this Act."
}